Recombinant Human p16-INK4a-TAT

Grouped product items
SizePrice Qty
5µg
$80.00
25µg
$195.00
100µg
$600.00
500µg
$1,800.00
1mg
$3,000.00
Catalog Number : 110-02T

description

p16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin dependent kinase-4 (CDK4) and CDK6. p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D. This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells. The expression of p16-INK4a steadily increases with age and tends to accumulate in stem cell compartments. The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas as well as in certain other types of cancer. P16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human p16-INK4a-TAT expressed in E. coli is a 18 kDa protein containing 167 amino-acid residues, including the 156 residues of full-length p16-INK4a and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR).

Additional Information

Source:
E. Coli
Purity:
Above 95% as determined by SDS-PAGE Analysis.
Cross Reactivity:
NULL
Biological Activity
Data not available.
AA Sequence
EPAAGSSME PSADWLATA AARGRVEEV RALLEAGAL PNAPNSYGR RPIQVMMMG SARVAELLL LHGAEPNCA DPATLTRPV HDAAREGFL DTLVVLHRA GARLDVRDA WGRLPVDLA EELGHRDVA RYLRAAAGG TRGSNHARI DAAEGPSDI PDGYGRKKR RQRRR
Research Interest:Stem Cell Research, Cancer
Cell Type:Stem Cells
Application:FA
Protein Cross Reactivity:NULL
© BioGems International, Inc. All rights reserved.